Moshe Elkabets presented research on the development of an AXL/PD-1 Bi-specific-Cell-Engager that targets AXL and PD1 (BiCE AXL/PD1) and increase the interaction between the AXL-expressing tumor cell and CD8+ T cells resulting in enhanced anti-tumor lytic activity of the T cells against AXL-expressing tumor cells (Yegodayev and Elkabets, 2025). Here, CD8A is linked to neoplasm.